NASDAQ: JUNSJupiter Neurosciences Inc Stock
$2.37-0.13 (-5.2%)
Updated Oct 29, 2026
JUNS Price
$2.37
Fair Value Price
N/A
Market Cap
$1.83M
52 Week Low
$2.25
52 Week High
$109.58
P/E
-0.12x
P/B
-4.99x
P/S
138.46x
PEG
N/A
Dividend Yield
N/A
Revenue
$64.69k
Earnings
-$9.20M
Gross Margin
81.8%
Operating Margin
-13,798.25%
Profit Margin
-14,220.1%
Debt to Equity
-11.16
Operating Cash Flow
-$7M
Beta
0.49
Next Earnings
Nov 13, 2026
Ex-Dividend
N/A
Next Dividend
N/A
JUNS Overview
Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues. Also in Phase II, JNS102 is being developed for mucopolysaccharidosis Type I, JNS107 for MELAS Syndrome, and JNS108 for mild cognitive impairment and early Alzheimer's disease. Furthermore, the company is progressing JNS109 for amyotrophic lateral sclerosis, JNS110 for traumatic brain injury and concussion, and JNS120 as a treatment for COVID-19. Founded in 2016, the company, formerly known as Jupiter Orphan Therapeutics, Inc., adopted its current name in August 2021 and is headquartered in Jupiter, Florida.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine JUNS's potential to beat the market
- JUNS doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
JUNS
RankedUnranked of 451
RankedUnranked of 451
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.54 | A | |
| $371.56 | A | |
| $10.95 | A |
Be the first to know about important JUNS news, forecast changes, insider trades & much more!
JUNS News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how JUNS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
JUNS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
JUNS is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
JUNS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more JUNS due diligence checks available for Premium users.
Valuation
JUNS fair value
Fair Value of JUNS stock based on Discounted Cash Flow (DCF)
Price
$2.37
Fair Value
-$3.34
Undervalued by
171.06%
JUNS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
JUNS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.12x
Industry
15.06x
Market
47.98x
JUNS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-4.99x
Industry
5.21x
JUNS's financial health
Profit margin
Revenue
$24.2k
Net Income
-$2.3M
Profit Margin
-9,380.9%
JUNS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
JUNS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$3.7M
Liabilities
$4.1M
Debt to equity
-11.16
JUNS's short-term liabilities ($3.88M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
JUNS's short-term assets ($2.55M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
JUNS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
JUNS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.3M
Investing
$0.0
Financing
$1.5M
JUNS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
JUNS vs Biotech Stocks
Jupiter Neurosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.